<DOC>
	<DOC>NCT02954341</DOC>
	<brief_summary>The purpose of this Post Approval Study (PAS) is to evaluate the use of the CardioMEMS HF System in patients with Class III Heart Failure in a commercial setting.</brief_summary>
	<brief_title>CardioMEMS HF System OUS Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Written informed consent obtained from subject &gt; 18 years of age Diagnosis of NYHA Class III Heart Failure At least 1 HF hospitalization within 12 months of Baseline visit Subjects with reduced LVEF heart failure should be receiving a beta blocker for 3 months and an ACEI or ARB for one month unless in the investigator's opinion, the subject is intolerant to beta blockers, ACEI or ARB. Subjects willing and able to comply with the followup requirements of the study Subjects with an active infection Subjects with history of recurrent (&gt; 1) pulmonary embolism or deep vein thrombosis Subjects who, in the Investigator's opinion, are unable to tolerate a right heart catheterization Subjects who have had a major cardiovascular event (e.g., myocardial infarction, open heart surgery, stroke, etc.) within 2 months of Baseline Visit Subjects with Cardiac Resynchronization Device (CRT) implanted &lt; 3 months prior to enrollment Subjects with a Glomerular Filtration Rate (GFR) &lt; 25 ml/min (obtained within 2 weeks of the baseline visit) who are nonresponsive to diuretic therapy or who are on chronic renal dialysis Subjects with congenital heart disease or mechanical right heart valve(s) Subjects likely to undergo heart transplantation or VAD within 6 months of baseline visit Subjects with known coagulation disorders Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel (not applicable for subjects taking anticoagulation therapy or other approved antiplatelets therapy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>